Company Profile
Tonix Pharmaceuticals Stock Price, News & Catalysts
- Ticker:
- TNXP
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
11.42 USD (-2.89%)
Close
Last updated: September 17, 2026
187M USD
Market cap
Why the stock is moving
As of Sep 17, 2026, TNXP closed down 2.89% at $11.42. No new same-company headline was identified in the current news window.
Company overview
Commercial Fibromyalgia Franchise
Tonix Pharmaceuticals is a commercial-stage biopharmaceutical company centered on TONMYA, a bedtime treatment for fibromyalgia. The product is intended to address nonrestorative sleep and other core features of the disease and represents the company's principal commercial franchise.
Infectious-Disease Pipeline
Beyond its commercial business, Tonix is developing TNX-4800, a long-acting human monoclonal antibody designed to prevent Lyme disease by targeting outer surface protein A on *Borrelia burgdorferi*.
Broader Development Platform
The company also maintains mid-stage and earlier-stage programs spanning immunology, infectious diseases and central nervous system disorders, giving it a mixed commercial-and-development-stage operating profile.
Future catalysts
- FDA meeting in 2026 to inform the design of the next Phase 2 study of TNX-1300 for cocaine intoxication.
- Initiation of the adaptive Phase 2 U.S. field study of TNX-4800 for Lyme-disease prevention in the first quarter of 2027, pending final FDA agreement.
- Topline data from the investigator-sponsored OASIS study of TNX-102 SL in acute stress reaction in mid-2027.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Tonix Pharmaceuticals (TNXP)?
Tonix Pharmaceuticals (TNXP) most recently closed at 11.42 USD, a -2.89% move versus the previous session.
What is the market cap of Tonix Pharmaceuticals (TNXP)?
Tonix Pharmaceuticals currently has a market capitalization of 187M USD on BioPharmSignal.
What does Tonix Pharmaceuticals do?
Commercial Fibromyalgia Franchise Tonix Pharmaceuticals is a commercial-stage biopharmaceutical company centered on TONMYA, a bedtime treatment for fibromyalgia. The product is intended to address nonrestorative sleep and other core features of the disease and represents the company's principal commercial franchise. Infectious-Disease Pipeline Beyond its...
On which exchange is TNXP stock listed?
Tonix Pharmaceuticals (TNXP) is associated with NASDAQ, United States, Biopharma.
What is TNX-4800?
field study of TNX-4800 for Lyme-disease prevention in the first quarter of 2027, pending final FDA agreement.
Which conditions is Tonix Pharmaceuticals targeting with TNX-4800?
Tonix Pharmaceuticals is associated with immunology based on its company overview and current catalyst commentary.
How does Tonix Pharmaceuticals describe recent progress with TNX-4800?
field study of TNX-4800 for Lyme-disease prevention in the first quarter of 2027, pending final FDA agreement.
What is TNX-1300?
FDA meeting in 2026 to inform the design of the next Phase 2 study of TNX-1300 for cocaine intoxication.